Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The active ingredients, human factor VIII and von Willebrand factor, replace the deficient proteins in the patient's blood. Factor VIII participates in the intrinsic coagulation cascade to generate thrombin, while von Willebrand factor promotes platelet adhesion and stabilizes factor VIII, together restoring normal clot formation.

The dose of Immunate is individualized. The prescribing clinician determines the amount and frequency based on the patient’s weight, severity of factor deficiency, and clinical response. Dosing regimens are not standardized and must follow the prescriber’s instructions.

Safety data for Immunate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should assess each case and discuss possible risks with the patient.

To order Immunate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Immunate combines both factor VIII and von Willebrand factor in a single intravenous preparation, which can simplify therapy for patients who need both proteins. Some alternatives provide only factor VIII or only von Willebrand factor, requiring separate products. Choice depends on the patient’s specific deficiency, clinical response, and physician preference.

Immunate must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. Do not use the product if it has been exposed to temperatures outside the recommended range.

Immunate is given by intravenous infusion. The healthcare professional prepares the dose according to the prescriber’s instructions and administers it through a sterile IV line, typically over several minutes, while monitoring the patient for any infusion‑related reactions.

The most serious risks include the development of inhibitory antibodies against factor VIII or von Willebrand factor, which can reduce efficacy, and rare but severe hypersensitivity reactions such as anaphylaxis. Thromboembolic events may also occur, especially if the product is used with other pro‑coagulant agents.

Immunate is contraindicated in patients with known hypersensitivity to any of its components, including human plasma‑derived proteins. It should also be avoided in individuals with a history of severe allergic reactions to factor concentrates until a thorough risk assessment is performed.